Skip to main content
Log in

Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data

European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

Allometric principles have been applied to scale and predict human pharmacokinetic parameters of irbesartan, an important AT1 receptor antagonist. The preclinical data gathered from rats, macaques (monkeys) and dogs were used in the allometric analysis. The use of these species was rationalized because preclinical models based on these species have been used in the evaluation pharmacodynamic activity of irbesartan. The human parameter values for clearance (CL/F), volume of distribution (V/F), and elimination rate constant (Kel) were scaled using simple allometry (CL/F, V/F and Kel) or with correction factors (CL/F). The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted=9 h; observed=10–20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted=456 L; observed=260 L). The present work presents an opportunity for prospective allometric scaling for the compounds belonging to this important therapeutic class.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cazaubon C., Gougat J., Bousquet F., Guiraudou P., Lacour C., Roccon A., Galindo G., Barthelemy G., Guatret B., Bernhardt C., Perreaut P., Breliere J-C., Le Fur G., Nisato D. (1993): Pharmacological characterization of SR 47436, a new nonpeptide AT1 angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther., 265, 826–834.

    CAS  PubMed  Google Scholar 

  2. Locour R., Canals F., Galindo G., Cazaubon C., Segondy D., Nisato D. (1993): Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive models. Eur. J. Pharmacol., 264, 307–316.

    Article  Google Scholar 

  3. Locour R., Roccon A., Cazaubon C., Segondy D., Nisato D. (1993): Pharmacological study of SR 47436, a non-peptide angiotensin II AT1 angiotensin receptor anatagonist, in conscious monkeys. J. Hypertens., 11, 1187–1194.

    Google Scholar 

  4. Roccon A., Marchionni D., Donat F., Segondy D., Cazaubon C., Nisato D. (1994): A pharmacological study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br. J. Pharmacol., 111, 145–150.

    CAS  PubMed  Google Scholar 

  5. Davi H., Tronquet G., Miscoria L., Perrier P., Dupont J., Caix J., Simland J., Berger Y. (2000): Disposition of irbesartan, an angiotensin H AT1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metabol. Dispos., 28, 79–88.

    CAS  Google Scholar 

  6. Wood J.M., Gulati N., Forgiarini P., Fuhrer W., Hofbauer K.G. (1985): Effects of a specific and long-acting rennin inhibitor in the marmoset. Hyperten., 7, 797–803.

    CAS  Google Scholar 

  7. Michel J.B., Wood J., Hofbauer K.G., Corvol P., Menard J. (1984): Blood pressure effects of rennin inhibitors by human renis antiserum in normotensive marmosets. Am. J. Phsiol., 246, 309–316.

    Google Scholar 

  8. DeGraaf G.L., Pals D.T., Cough S.J., Lawson J.A. (1993): Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in honhuman primates. J. Pharmacol. Exp. Ther., 263, 6–10.

    Google Scholar 

  9. Huang X.H., Qiu F.R., Xie H.T., Li J. (2005): Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorthiazide in renal hypertensive dogs. J. Cardiovasc. Pharmacol., 46, 863–869.

    Article  CAS  PubMed  Google Scholar 

  10. Chando T.J., Evertt D.W., Kahle A.D., Starrett A.M., Vachharajani N., Shyu W.C., Kripalani K.J., Barbhaiya R.H. (1998): Biotransformation of irbesartan in man. Drug Metabol. Dispos., 26, 408–417.

    CAS  Google Scholar 

  11. Vachharajani N.N., Shyu W.C., Chando T.J., Everett D.W., Greene D.S., Barbhaiya R.H. (1998): Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J. Clin. Pharmacol., 38, 702–707.

    CAS  PubMed  Google Scholar 

  12. Marino M.R., Langenbacher K.M., Raymond R.H., Ford N.F., Lasseter K.C. (1998): Pharmacokinetics and pharmacodynamics of Irbesertan in patients with hepatic cirrhosis. J. Clin. Pharmacol., 38, 345–356.

    Google Scholar 

  13. Webrer B. (2000): A review of clinical experience with the Angiotensin II receptor antagonist Irbesertan, Cardiovasc. Drug Rev., 18, 103–126.

    Google Scholar 

  14. Mahmood I., Balian J.D. (1996): Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci., 85, 411–414.

    Article  CAS  PubMed  Google Scholar 

  15. Mahmood I., Sahawalla C. (2002): Interspecies scaling of biliary excreted drugs. J. Pharm. Sci., 91, 1908–1914.

    Article  CAS  PubMed  Google Scholar 

  16. Ahlawat P., Srinivas N.R. (2008): Allometric prediction of the human pharmacokinetic parameters for naveglitazar. Eur. J. Drug Metabol. Pharmacokinet., 3, 187–190.

    Google Scholar 

  17. Ahlawat P., Srinivas N.R. (2009): Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data. Xenobiotica, 38, 1377–1385.

    Article  Google Scholar 

  18. Boxembaun H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokin. Biopharmacol., 10, 201–227.

    Article  Google Scholar 

  19. Mahmood I. (2005): Interspecies scaling of biliary excreted drugs: a comparison of several methods. J. Pharm. Sci., 94, 883–892.

    Article  CAS  PubMed  Google Scholar 

  20. Pavan Kumar V.V., Vinu C.A., Mullangi R., Srinivas N.R. (2007): Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. Eur. J. Drug Metabol. Pharmacokinet., 32, 29–37.

    Google Scholar 

  21. Perrier L., Bourrie M., Martil E., Tronquet C., Masse D., Berger Y., Magdalou J., Fabre G. (1994): In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J. Pharmacol. Exp. Ther., 271, 91–99.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nuggehally R. Srinivas PhD, FCP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pavan Kumar, V.V., Srinivas, N.R. Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. Eur. J. Drug Metabol. Pharmacokinet. 33, 247–252 (2008). https://doi.org/10.1007/BF03190880

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190880

Key words

Navigation